- Home
- ADXN vs GTBP Comparison
ADXN vs GTBP Comparison
Compare ADXN & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- GTBP
- Stock Information
- Founded
- ADXN 2002
- GTBP 1965
- Country
- ADXN Switzerland
- GTBP United States
- Employees
- ADXN N/A
- GTBP N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- GTBP Health Care
- Exchange
- ADXN Nasdaq
- GTBP Nasdaq
- Market Cap
- ADXN 8.0M
- GTBP 5.5M
- IPO Year
- ADXN N/A
- GTBP N/A
- Fundamental
- Price
- ADXN $10.85
- GTBP $0.79
- Analyst Decision
- ADXN Strong Buy
- GTBP Strong Buy
- Analyst Count
- ADXN 1
- GTBP 1
- Target Price
- ADXN $30.00
- GTBP $11.00
- AVG Volume (30 Days)
- ADXN 61.3K
- GTBP 449.7K
- Earning Date
- ADXN 09-01-2025
- GTBP 11-13-2025
- Dividend Yield
- ADXN N/A
- GTBP N/A
- EPS Growth
- ADXN N/A
- GTBP N/A
- EPS
- ADXN 0.10
- GTBP N/A
- Revenue
- ADXN $278,508.00
- GTBP N/A
- Revenue This Year
- ADXN $86.57
- GTBP N/A
- Revenue Next Year
- ADXN N/A
- GTBP N/A
- P/E Ratio
- ADXN $0.84
- GTBP N/A
- Revenue Growth
- ADXN N/A
- GTBP N/A
- 52 Week Low
- ADXN $6.51
- GTBP $0.63
- 52 Week High
- ADXN $12.05
- GTBP $4.10
- Technical
- Relative Strength Index (RSI)
- ADXN 68.95
- GTBP 29.57
- Support Level
- ADXN $8.88
- GTBP $0.63
- Resistance Level
- ADXN $12.05
- GTBP $0.85
- Average True Range (ATR)
- ADXN 0.47
- GTBP 0.10
- MACD
- ADXN 0.28
- GTBP 0.03
- Stochastic Oscillator
- ADXN 72.41
- GTBP 31.22
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.